PharmaMar signs licensing agreement in Turkey with EczacA[+ or -]baAYA[+ or -] for anticancer drug Aplidin.
M2 EQUITYBITES-May 26, 2017-PharmaMar signs licensing agreement in Turkey with EczacA[+ or -]baAYA[+ or -] for anticancer drug Aplidin
(C)2017 M2 COMMUNICATIONS http://www.m2.com
Healthcare company PharmaMar (MCE:PHM) stated on Thursday that it plans to commercialise the marine-derived anticancer drug Aplidin (plitidepsin) in Turkey in a licensing agreement with Eczac?bas? Group.
This agreement will provide PharmaMar with an upfront payment as well as development milestones related to the health approval procedure of Aplidin in Turkey.
In conjunction with the agreement, PharmaMar will retain exclusive production rights and will supply the finished product to Eczac?bas? for commercial use.
According to PharmaMar, Aplidin is its second most advanced anticancer drug that is currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma.
The company stated that plitidepsin has shown positive results in a pivotal Phase III clinical trial (ADMYRE) for multiple myeloma[i] and in September 2016. It has submitted the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for plitidepsin in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM).
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||May 26, 2017|
|Previous Article:||Brinker International's board approves 6% higher dividend of USD0.34 per share.|
|Next Article:||Allstate announces common and preferred stock dividends.|